Pharmaceutical composition containing anti-Nectin-4 antibody drug conjugate and application thereof
Patent Information
- Application Number
- CN202380034404.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-16
- Filing Date
- 2023-05-16
- Publication Date
- 2024-11-22
AI Technical Summary
Existing anti-tumor drug conjugates (ADCs) face stability and targeting challenges when treating tumors. In particular, targeted drugs targeting nectin-4 are difficult to effectively target specific tumor cells, and there are drug loads and buffers. Concentration instability problem.
A pharmaceutical composition containing an anti-Nectin-4 antibody-drug conjugate was developed, using an antibody with the NEC49-9-A structure combined with a histidine-histidine hydrochloride buffer to control the pH value between 5.0 and 6.5. , and add surfactants and sugars to optimize drug loading and buffer concentration to improve drug stability and targeting efficiency.
The stability and targeting of the pharmaceutical composition are improved, ensuring effective killing of cells with high Nectin-4 expression, reducing side effects, and improving therapeutic effect and safety.
Abstract
Description
A pharmaceutical composition containing an anti-nectin-4 antibody-drug conjugate and its use
[0001] This application claims priority to Chinese patent application CN202210530522.7 filed on May 16, 2022. Technical Field
[0002] The present disclosure belongs to the field of pharmaceutical preparations, and specifically relates to a pharmaceutical composition comprising an anti-nectin-4 antibody-drug conjugate, and its use as an anti-cancer drug. Background Art
[0003] The statements herein merely provide background information related to the present disclosure and do not necessarily constitute prior art.
[0004] Nectin-4 (PVRL4) is a 66kDa type I transmembrane glycoprotein belonging to the nectin family of the Ig superfamily. It plays a key role in various biological processes (proliferation, differentiation, and migration) in epithelial cells, endothelial cells, immune cells, and neural cells. Studies have shown that nectin-4 plays an important role in the development, invasion, and metastasis of malignant tumors such as bladder cancer, breast cancer, and lung cancer. This role is associated with the activation of Cdc42 and Rac and alterations in the cytoskeletal actin, which in turn promotes tumor cell proliferation, invasion, and metastasis.
[0005] Nectin-4 is a tumor-specific antigen expressed in 50%, 49%, and 86% of bladder, breast, and lung cancers, respectively. It is often found in tumors with poor prognosis, but its expression is undetectable in most normal tissues. This information suggests that nectin-4 could be an ideal target for cancer therapy.
[0006] Enfortumab vedotin (Padcev) is a nectin-4-targeting conjugate conjugated to MMAE. The development of more antibody-drug conjugates targeting nectin-4 as anti-tumor drugs is of great significance.
[0007] ADCs have a more complex and heterogeneous structure than antibodies, thus posing greater challenges to ADC formulation for therapeutic purposes.
[0008] Summary of the Invention
[0009] The present disclosure provides a pharmaceutical composition comprising an antibody drug conjugate and a buffer, wherein the antibody drug conjugate has a structure as shown in Formula NEC49-9-A:
[0010] in:
[0011] NEC49 is an anti-nectin-4 antibody comprising heavy chain HCDR1, HCDR2, and HCDR3 as set forth in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10; and light chain LCDR1, LCDR2, and LCDR3 as set forth in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13; preferably, comprising a heavy chain variable region as set forth in SEQ ID NO:4 and a light chain variable region as set forth in SEQ ID NO:5; more preferably, comprising a heavy chain as set forth in SEQ ID NO:6 and a light chain as set forth in SEQ ID NO:7;
[0012] n is a decimal or integer from 1 to 10, preferably from 1 to 8, more preferably from 3 to 5;
[0013] The buffer is histidine-histidine hydrochloride buffer,
[0014] The pH of the pharmaceutical composition is about 5.0 to about 6.5, preferably about 5.5 to about 6.5, and more preferably about 5.9 to about 6.2.
[0015] The present disclosure provides a pharmaceutical composition comprising an antibody drug conjugate and a buffer, wherein the antibody drug conjugate has a structure as shown in Formula NEC49-9-A:
[0016] in:
[0017] NEC49 is an anti-nectin-4 antibody, which is derived from the antibody NEC49 of PCT application PCT / CN2022 / 089129, and comprises a heavy chain variable region as shown in SEQ ID NO: 4 and a light chain variable region as shown in SEQ ID NO: 5;
[0018] n is a decimal or integer from 1 to 10, preferably from 1 to 8, more preferably from 3 to 5, most preferably from about 3.5 to 4.7;
[0019] The buffer is histidine-histidine hydrochloride buffer, and the pH of the composition is about 5.0 to about 6.5, preferably about 5.5 to about 6.5, and more preferably about 5.9 to about 6.2.
[0020] In an alternative embodiment, the anti-nectin-4 antibody NEC49 in the pharmaceutical composition comprises a heavy chain as shown in SEQ ID NO: 6 (SEQ ID NO: 21 in PCT / CN2022 / 089129) and a light chain as shown in SEQ ID NO: 7 (SEQ ID NO: 22 in PCT / CN2022 / 089129):
[0021] NEC49 heavy chain:
[0022] NEC49 light chain:
[0023] In an alternative embodiment, the pH value in the pharmaceutical composition is about 5.0 to about 6.5, non-limiting examples include about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, and any range between these points; preferably the pH is about 5.5 to about 6.5, and more preferably the pH is about 5.9 to about 6.2.
[0024] In alternative embodiments, the buffer concentration in the pharmaceutical composition is from about 5 mM to about 50 mM, non-limiting examples of which include 5 mM, 10 mM, 12 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, 35 mM, 40 mM, 45 mM, 50 mM and any range therebetween, preferably from about 10 mM to about 50 mM, more preferably from about 20 mM to about 40 mM; and most preferably about 30 mM.
[0025] In an optional embodiment, the pharmaceutical composition further comprises a surfactant. The surfactant may be selected from polysorbate, polysorbate 20, polysorbate 80, polyhydroxyalkylene, Triton, sodium dodecyl sulfate, sodium lauryl sulfate, sodium octyl glucoside, lauryl-sulfobetaine, myristyl-sulfobetaine, linoleyl-sulfobetaine, stearyl-sulfobetaine, lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine, stearyl-sarcosine, linoleyl-betaine, myristyl-betaine, cetyl-betaine, Cinnamyl-betaine, cocamidopropyl-betaine, linoleamidopropyl-betaine, myristamidopropyl-betaine, palmitamidopropyl-betaine, isostearamidopropyl-betaine, myristamidopropyl-dimethylamine, palmitamidopropyl-dimethylamine, isostearamidopropyl-dimethylamine, methyl cocoyl sodium, methyl oleyl taurate sodium, polyethylene glycol, polypropylene glycol and copolymer of ethylene and propylene glycol, etc. Preferred surfactants are polysorbate 80 or polysorbate 20, more preferably polysorbate 80.
[0026] In alternative embodiments, the concentration of the surfactant in the pharmaceutical composition is from about 0.01 mg / mL to about 1.0 mg / mL, preferably from about 0.05 mg / mL to about 0.6 mg / mL, further preferably from about 0.05 mg / mL to about 0.4 mg / mL, more preferably from about 0.1 mg / mL to about 0.3 mg / mL, or from about 0.2 mg / mL to about 0.6 mg / mL, and most preferably about 0.2 mg / mL, non-limiting examples include about 0.01 mg / mL, 0.02 mg / mL, 0.05 mg / mL, 0.1 mg / mL, 0.15 mg / mL, 0.2 mg / mL, 0.25 mg / mL, 0.3 mg / mL, 0.35 mg / mL, 0.4 mg / mL, 0.45 mg / mL, 0.5 mg / mL, 0.6 mg / mL, 0.7 mg / mL, 0.8 mg / mL, 0.9 mg / mL, 1.0 mg / mL, and any range therebetween.
[0027] In an optional embodiment, the aforementioned pharmaceutical composition further comprises sugar. The "sugar" disclosed herein comprises a conventional composition (CH2O) n and derivatives thereof, including monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, non-reducing sugars, and the like. The sugar may be selected from glucose, sucrose, trehalose, α,α-trehalose dihydrate, lactose, fructose, maltose, dextran, glycerol, erythritol, glycerol, arabitol, sylitol, sorbitol, mannitol, milibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, sorbitol, maltitol, lactitol, iso-maltulose, and the like. The preferred sugar is a non-reducing disaccharide, more preferably α,α-trehalose dihydrate or sucrose, and most preferably sucrose.
[0028] In an alternative embodiment, the concentration of sugar in the aforementioned pharmaceutical composition is about 25 mg / mL to about 80 mg / mL, preferably about 30 mg / mL to about 50 mg / mL, non-limiting examples include 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, 50 mg / mL, 55 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL and any range between these points, preferably 40 mg / mL.
[0029] In an optional embodiment, the aforementioned pharmaceutical composition further comprises an amino acid, and the amino acid is preferably glycine.
[0030] In alternative embodiments, the concentration of the amino acid in the aforementioned pharmaceutical composition is from about 6 mg / mL to about 15 mg / mL, from about 7 mg / mL to about 11 mg / mL, preferably from about 7 mg / mL to about 10 mg / mL, more preferably from about 7 mg / mL to about 9 mg / mL, from about 8 mg / mL to about 9 mg / mL, non-limiting examples include about 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.2 mg / mL, 7.6 mg / mL, 7.8 mg / mL, 8 mg / mL, 8.5 mg / mL, 9 mg / mL, 9.5 mg / mL, 10 mg / mL, 10.2 mg / mL, 11 mg / mL, 12 mg / mL, 13 mg / mL, 14 mg / mL, 15 mg / mL and any range therebetween, most preferably about 9 mg / mL.
[0031] In an alternative embodiment, the concentration of glycine in the aforementioned pharmaceutical composition is from about 6 mg / mL to about 15 mg / mL, from about 7 mg / mL to about 11 mg / mL, preferably from about 7 mg / mL to about 10 mg / mL, more preferably from about 7 mg / mL to about 9 mg / mL, from about 8 mg / mL to about 9 mg / mL, non-limiting examples include about 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.2 mg / mL, 7.6 mg / mL, 7.8 mg / mL, 8 mg / mL, 8.5 mg / mL, 9 mg / mL, 9.5 mg / mL, 10 mg / mL, 10.2 mg / mL, 11 mg / mL, 12 mg / mL, 13 mg / mL, 14 mg / mL, 15 mg / mL and any range therebetween, most preferably about 9 mg / mL.
[0032] In an alternative embodiment, the concentration of the antibody drug conjugate in the pharmaceutical composition is about 1 mg / mL to about 100 mg / mL, based on protein concentration, non-limiting examples of which include 1 mg / mL, 10 mg / mL, 11 mg / mL, 12 mg / mL, 13 mg / mL, 14 mg / mL, 15 mg / mL, 16 mg / mL, 17 mg / mL, 18 mg / mL, 19 mg / mL, 20 mg / mL, 21 mg / mL, 22 mg / mL, 23 mg / mL, 24 mg / mL, 25 mg / mL, 26 mg / mL, mL, 27 mg / mL, 28 mg / mL, 29 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL and any range therebetween; preferably, the antibody drug conjugate concentration is about 10 mg / mL to about 30 mg / mL based on protein concentration; more preferably, the antibody drug conjugate concentration is about 18 mg / mL to about 22 mg / mL based on protein concentration; most preferably, it is about 20 mg / mL. Specific, non-limiting examples include 20.1 mg / mL, 20.2 mg / mL, 20.3 mg / mL, 20.4 mg / mL, 20.5 mg / mL, 20.6 mg / mL, 20.7 mg / mL, 20.8 mg / mL, 20.81 mg / mL, 20.82 mg / mL, 20.83 mg / mL, 20.84 mg / mL, 20.85 mg / mL, 20.86 mg / mL, 20.87 mg / mL, 20.88 mg / mL, 20.89 mg / mL, 20.9 mg / mL, 20.91 mg / mL, 20.92 mg / mL, 20.93 mg / mL, 20.94 mg / mL, 20.95 mg / mL, 20.96 mg / mL, 20.97 mg / mL, 20.98 mg / mL, 20.99 mg / mL, 21 mg / mL, and any range therebetween. The term "protein concentration" refers to the concentration of the antibody portion of the antibody drug conjugate.
[0033] In alternative embodiments, the drug loading (n) can range from the average number of cytotoxic drugs bound to each anti-nectin-4 antibody, non-limiting examples of which include the average number of cytotoxic drugs bound to each antibody of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and any range between these values. Preferably, the drug loading (n) is selected from 1-10, 1-8, 2-8, 2-7, 2-6, 2-5, 2-4, 3-4, 3-5, 3.5-4.7, 5-6, 5-7, 5-8, and 6-8. Exemplarily, the drug loading (n) can be the average of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. n is a decimal or an integer.
[0034] In alternative embodiments, the drug loading (n) is about 3.5-4.7.
[0035] In an alternative embodiment, the drug loading (n) is about 4.
[0036] In an optional embodiment, the pharmaceutical composition comprises:
[0037] (a) about 1 mg / mL to about 100 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.05 mg / mL to about 0.4 mg / mL of polysorbate, (c) about 30 mg / mL to about 50 mg / mL of sucrose or α,α-trehalose dihydrate, (d) about 6 mg / mL to about 15 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5 to 6.5.
[0038] In an optional embodiment, the pharmaceutical composition comprises:
[0039] (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate, (c) about 30 mg / mL to about 50 mg / mL of sucrose or α,α-trehalose dihydrate, (d) about 7 mg / mL to about 11 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5 to 6.5.
[0040] In an optional embodiment, the pharmaceutical composition comprises:
[0041] (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate 80, (c) about 30 mg / mL to about 50 mg / mL of sucrose, (d) about 7 mg / mL-11 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5-6.5.
[0042] In an optional embodiment, the pharmaceutical composition comprises:
[0043] (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate 80, (c) about 30 mg / mL to about 50 mg / mL of sucrose, (d) about 7 mg / mL-11 mg / mL of glycine, and (e) about 20 mM to about 40 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5-6.5.
[0044] In an optional embodiment, the pharmaceutical composition comprises:
[0045] (a) about 18 mg / mL to about 22 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.2 mg / mL of polysorbate 80, (c) about 40 mg / mL of sucrose, (d) about 9 mg / mL of glycine, and (e) about 30 mM histidine-histidine hydrochloride buffer, wherein the pH of the pharmaceutical composition is about 5.9-6.2.
[0046] In an optional embodiment, the pharmaceutical composition comprises:
[0047] (a) about 20 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.2 mg / mL of polysorbate 80, (c) about 40 mg / mL of sucrose, (d) about 9 mg / mL of glycine, and (e) about 30 mM histidine-histidine hydrochloride buffer, wherein the pH of the pharmaceutical composition is about 6.0.
[0048] In an optional embodiment, any of the aforementioned pharmaceutical compositions is a liquid formulation. The liquid formulation or the reconstituted formulation disclosed herein has good stability. Furthermore, a stable liquid formulation includes a liquid formulation that exhibits the desired characteristics when stored at a temperature of 40° C. or above for one month.
[0049] The present disclosure also provides a lyophilized formulation containing an antibody drug conjugate, characterized in that the formulation can form the pharmaceutical composition described above after reconstitution.
[0050] The present disclosure also provides a method for preparing a lyophilized formulation containing an antibody drug conjugate, which comprises the step of freeze-drying the pharmaceutical composition as described above.
[0051] In an alternative embodiment, the freeze drying process comprises, in a method for preparing a lyophilized formulation comprising an antibody drug conjugate, the steps of pre-freezing, primary drying, and secondary drying. Freeze drying is performed by freezing the formulation and then allowing water to sublime at a temperature suitable for primary drying. Under these conditions, the product temperature is below the eutectic point or collapse temperature of the formulation. Typically, the primary drying temperature ranges from about -30°C to 25°C (assuming the product remains frozen during the primary drying process). The formulation, the size and type of container (e.g., glass vial) holding the sample, and the volume of liquid determine the time required for drying, which can range from several hours to several days (e.g., 40-60 hours). The secondary drying stage can be performed at a temperature of about 0°C to 40°C, depending primarily on the type and size of the container and the type of protein used. The secondary drying time is determined by the desired residual moisture level in the product and typically requires at least about 5 hours. Typically, the water content of the lyophilized formulation is less than about 5%, preferably less than about 3%. The pressure can be the same as that applied in the primary drying step, preferably, the pressure of the secondary drying is lower than that of the primary drying. Freeze drying conditions can vary with the formulation and vial size.
[0052] In an optional embodiment of the present disclosure, 4.4 mL of the composition stock solution is freeze-dried, and the freeze-drying procedure is as follows: the pre-freezing temperature is 5°C and -45°C, respectively, the primary drying temperature is -20°C, the vacuum degree is 10 Pa, and the secondary drying temperature is 25°C, and the vacuum degrees are 10 Pa and 1 Pa, respectively.
[0053] In some embodiments, the lyophilized formulation is stable at 40°C for at least 7 days, at least 14 days, at least 28 days, or at least 30 days.
[0054] The present disclosure also provides a lyophilized formulation comprising an antibody drug conjugate, wherein the lyophilized formulation is obtained by freeze-drying the pharmaceutical composition of the antibody drug conjugate as described above.
[0055] The present disclosure also provides a reconstituted solution containing an antibody drug conjugate, characterized in that the reconstituted solution is prepared by reconstituted the lyophilized preparation as described above.
[0056] The present disclosure also provides a method for preparing the aforementioned reconstituted solution, which comprises the step of reconstituted the aforementioned lyophilized preparation, wherein the solution used for reconstitution is selected from but not limited to water for injection, physiological saline or glucose solution.
[0057] In an optional embodiment, the aforementioned reconstitution solution comprises:
[0058] (a) about 1 mg / mL to about 100 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.05 mg / mL to about 0.4 mg / mL of polysorbate, (c) about 30 mg / mL to about 50 mg / mL of sucrose or α,α-trehalose dihydrate, (d) about 6 mg / mL to about 15 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5 to 6.5.
[0059] In an optional embodiment, the aforementioned reconstitution solution comprises:
[0060] (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate, (c) about 30 mg / mL to about 50 mg / mL of sucrose or α,α-trehalose dihydrate, (d) about 7 mg / mL to about 11 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5 to 6.5.
[0061] In an optional embodiment, the aforementioned reconstitution solution comprises:
[0062] (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate 80, (c) about 30 mg / mL to about 50 mg / mL of sucrose, (d) about 7 mg / mL to about 11 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pharmaceutical composition having a pH of about 5.5 to 6.5.
[0063] In an optional embodiment, the aforementioned reconstitution solution comprises:
[0064] (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate 80, (c) about 30 mg / mL to about 50 mg / mL of sucrose, (d) about 7 mg / mL to about 11 mg / mL of glycine, and (e) about 20 mM to about 40 mM histidine-histidine hydrochloride buffer; the pharmaceutical composition having a pH of about 5.5 to 6.5.
[0065] In an optional embodiment, the aforementioned reconstitution solution comprises:
[0066] (a) about 18 mg / mL to about 22 mg / mL of the antibody drug conjugate, (b) about 0.2 mg / mL of polysorbate 80, (c) about 40 mg / mL of sucrose, (d) about 9 mg / mL of glycine, and (e) about 30 mM histidine-histidine hydrochloride, wherein the pH of the pharmaceutical composition is about 5.9 to 6.2.
[0067] In an optional embodiment, the aforementioned reconstitution solution comprises:
[0068] (a) about 20 mg / mL of the antibody drug conjugate, (b) about 0.2 mg / mL of polysorbate 80, (c) about 40 mg / mL of sucrose, (d) about 9 mg / mL of glycine, and (e) about 30 mM histidine-histidine hydrochloride, wherein the pH of the pharmaceutical composition is about 6.0.
[0069] The present disclosure also provides a medicine kit, which includes a container containing the pharmaceutical composition, lyophilized preparation or reconstituted solution as described above. In some embodiments, the container is a neutral borosilicate glass tube injection bottle.
[0070] The present disclosure also provides use of the aforementioned pharmaceutical composition, lyophilized preparation, or reconstituted solution in the preparation of a drug for treating or preventing tumors.
[0071] The present disclosure also provides a method for treating a disease, comprising administering a therapeutically or prophylactically effective amount of the aforementioned pharmaceutical composition, lyophilized formulation, reconstituted solution, or kit to a subject in need thereof.
[0072] The present disclosure also provides the aforementioned pharmaceutical composition, or lyophilized preparation, or reconstituted solution, or drug kit as a medicament for treating or preventing a disease.
[0073] The present disclosure also provides the aforementioned pharmaceutical composition, or lyophilized preparation, or reconstituted solution, or drug kit as a drug for treating or preventing tumors.
[0074] In an alternative embodiment, the disease or tumor is a disease or condition mediated by Nectin-4.
[0075] The present disclosure also provides the use of the aforementioned pharmaceutical composition, or lyophilized preparation, or reconstituted solution, or kit as a drug in the preparation of a drug for treating viral infection, tumor or cancer, wherein the tumor or cancer is selected from urothelial carcinoma (e.g., metastatic urothelial carcinoma, locally advanced urothelial carcinoma), ureteral cancer, breast cancer, pancreatic cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), kidney cancer (e.g., renal cell carcinoma), liver cancer (e.g., hepatocellular carcinoma), esophageal cancer (also known as "esophageal cancer"), laryngeal tumors, pharyngeal tumors, oral tumors, gastric cancer, ovarian cancer, prostate cancer (e.g., metastatic castration-resistant prostate cancer), bladder cancer (locally advanced bladder cancer), colorectal cancer (including colon cancer and rectal cancer), head and neck cancer, squamous cell carcinoma and melanoma.
[0076] In some embodiments, the pharmaceutical composition, lyophilized formulation, reconstituted solution, or kit as described in any one of the above is an intravenous injection formulation, a subcutaneous injection formulation, an intraperitoneal injection formulation, or an intramuscular injection formulation. In some embodiments, it is an intravenous injection formulation.
[0077] As is well known to those skilled in the art, one, some or all of the features of the various embodiments described in this disclosure may be further combined to form other embodiments of the present disclosure. The above embodiments of the present disclosure and other embodiments obtained by combination are further described in detail below. DETAILED DESCRIPTION
[0078] The present disclosure provides a pharmaceutical composition that is more convenient for production and administration and has stable performance. Undesirable instability may include any one or more of the following: aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), clipping / hydrolysis / fragmentation (e.g., hinge region fragmentation), succinimide formation, unpaired cysteine residues, toxin dissociation, etc. Specifically, the pharmaceutical composition described herein comprises an antibody drug conjugate and a buffer.
[0079] the term
[0080] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise explicitly defined herein, all other technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the present disclosure belongs.
[0081] An antibody-drug conjugate (ADC) is a conjugate formed by linking an antibody (or its antigen-binding fragment) with a biologically active cytotoxin or a small molecule drug with cell-killing activity through a linker.
[0082] "Drug loading" or "drug loading" is also called the drug-to-antibody ratio (DAR), which is the average number of drugs conjugated to each antibody in the ADC. It can be, for example, in the range of about 1 to about 10 drugs conjugated to each antibody, and in certain embodiments, in the range of about 1 to about 8 drugs conjugated to each antibody, preferably an integer or decimal selected from 1-8, 2-8, 2-7, 2-6, 2-5, 2-4, 3-4, 3-5, 3-6, 4-5, 5-6, 5-7, 5-8, 6-7, and 6-8. Exemplarily, the drug loading can be the mean of any of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. The ADC formula disclosed herein includes a collection of antibodies conjugated to drugs within the aforementioned ranges. In embodiments disclosed herein, the drug loading can be represented by n. Drug loading can be determined by conventional methods such as UV / visible spectroscopy, mass spectrometry, ELISA assays, and HPLC.
[0083] The term "linker unit" or "connection fragment" or "connection unit" refers to a chemical structure fragment or bond that is connected to an antibody or its antigen-binding fragment at one end and to a drug at the other end, and can also be connected to other linkers before being connected to the drug.
[0084] Linkers, including extenders, spacers, and amino acid units, can be synthesized by methods known in the art, such as those described in US20050238649A1. The linker can be a "cleavable linker" that facilitates release of the drug in the cell. For example, an acid-labile linker (e.g., a hydrazone), a protease-sensitive (e.g., a peptidase-sensitive) linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker can be used (Chari et al., Cancer Research 52:127-131 (1992); U.S. Patent No. 5,208,020).
[0085] The term "drug linker fragment" or "drug-linker fragment" refers to a fragment formed by linking a drug to a linker unit, which can be linked to an antibody or its antigen-binding fragment through the other end of the linker unit.
[0086] Cytotoxic drug loading can be controlled by the following non-limiting methods, including:
[0087] (1) Control the molar ratio of the drug-linker fragment and the antibody,
[0088] (2) Control reaction time and temperature,
[0089] (3) Select different reaction reagents.
[0090] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).
[0091] The term "antibody" as used herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), as long as they exhibit the desired antigen-binding activity.
[0092] The engineered antibodies or antigen-binding fragments disclosed herein can be prepared and purified using conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into GS expression vectors. The recombinant immunoglobulin expression vector can be stably transfected into CHO cells. As a more recommended existing technology, mammalian expression systems will result in glycosylation of antibodies, especially at the highly conserved N-terminal site in the Fc region. Positive clones are expanded in serum-free culture medium in a bioreactor to produce antibodies. The culture fluid that secretes antibodies can be purified using conventional techniques. For example, purification can be performed using an A or G Sepharose FF column containing an adjusted buffer. Non-specifically bound components are washed away. The bound antibodies are then eluted using a pH gradient method, and the antibody fragments are detected by SDS-PAGE and collected. The antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieves and ion exchange. The obtained product should be immediately frozen, such as at -70°C, or freeze-dried.
[0093] "Buffer" refers to a buffer that tolerates changes in pH through the action of its acid-base conjugate components. Examples of buffers that control pH within an appropriate range include acetate, succinate, gluconate, histidine, oxalate, lactate, phosphate, citrate, tartrate, fumarate, glycylglycine, and other organic acid buffers.
[0094] "Histidine buffer" is a buffer containing histidine. Examples of histidine buffers include histidine-histidine hydrochloride, histidine-histidine acetate, histidine-histidine phosphate, histidine-histidine sulfate, and the like, with histidine-histidine hydrochloride buffer being preferred. Histidine-histidine hydrochloride buffer can be prepared from histidine and hydrochloric acid, or from histidine and histidine hydrochloride.
[0095] "Citrate buffer" is a buffer comprising citrate ions. Examples of citrate buffers include citric acid-sodium citrate, citric acid-potassium citrate, citric acid-calcium citrate, citric acid-magnesium citrate, and the like. A preferred citrate buffer is citric acid-sodium citrate.
[0096] A "succinate buffer" is a buffer comprising succinate ions. Examples of succinate buffers include succinic acid-sodium succinate, succinic acid-potassium succinate, succinic acid-calcium succinate, and the like. A preferred succinate buffer is succinic acid-sodium succinate. For example, the succinic acid-sodium succinate can be prepared from succinic acid and sodium hydroxide, or from succinic acid and sodium succinate.
[0097] "Phosphate buffer" is a buffer containing phosphate ions. Examples of phosphate buffers include disodium hydrogen phosphate-sodium dihydrogen phosphate, disodium hydrogen phosphate-potassium dihydrogen phosphate, disodium hydrogen phosphate-citric acid, and the like. A preferred phosphate buffer is disodium hydrogen phosphate-sodium dihydrogen phosphate.
[0098] An "acetate buffer" is a buffer comprising acetate ions. Examples of acetate buffers include acetic acid-sodium acetate, histidine-histidine acetate, acetic acid-potassium acetate, acetic acid-calcium acetate, acetic acid-magnesium acetate, and the like. A preferred acetate buffer is acetic acid-sodium acetate.
[0099] A "pharmaceutical composition" refers to a mixture containing one or more antibody-drug conjugates described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to maintain the stability of the antibody active ingredient, facilitate administration to an organism, and promote absorption of the active ingredient, thereby exerting its biological activity.
[0100] In the present disclosure, "pharmaceutical composition" and "formulation" are not mutually exclusive.
[0101] Unless otherwise specified, the solvent in the solution form of the pharmaceutical composition described in the present disclosure is water.
[0102] "Lyophilized formulation" refers to a pharmaceutical composition in liquid or solution form or a formulation or pharmaceutical composition obtained after a liquid or solution formulation has been subjected to a vacuum freeze-drying step.
[0103] As used herein, the terms "about" and "approximately" refer to values that are within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how it is measured or determined (i.e., the limits of the measurement system). For example, in each practice in the art, "about" can mean within 1 or more than 1 standard deviation. Alternatively, "about" or "substantially comprising" can mean a range of up to 20%. In addition, particularly for biological systems or processes, the term can mean up to an order of magnitude or up to 5 times the value. Unless otherwise indicated, when a specific value appears in the application and claims, the meaning of "about" or "substantially comprising" should be assumed to be within an acceptable error range for that specific value.
[0104] The pharmaceutical compositions disclosed herein can achieve a stable effect: the antibody drug conjugate therein substantially retains its physical stability and / or chemical stability and / or biological activity after storage; preferably, the pharmaceutical composition substantially retains its physical and chemical stability and its biological activity after storage. The storage period is generally selected based on the intended shelf life of the pharmaceutical composition. Currently, there are various analytical techniques for measuring the stability of protein or antibody drug conjugates, which can measure stability after storage at a selected temperature for a selected period of time.
[0105] A stable formulation is one in which no significant changes are observed after storage at refrigerated temperatures (2-8°C) for at least 3 months, preferably 6 months, and more preferably 1 year. Additionally, stable liquid formulations include those that exhibit the desired characteristics after storage at 25°C for periods of time including 1 month, 2 months, or 3 months. Furthermore, stable liquid formulations include those that exhibit the desired characteristics after storage at 40°C for periods of time including 10 days, 20 days, or 1 month. Typical examples of stability include: typically no more than about 10%, preferably no more than about 5%, of antibody monomers aggregate or degrade as measured by SEC-HPLC. Visually, the formulation is a pale yellow, nearly colorless, clear liquid, or colorless, or clear to slightly opalescent. The concentration, pH, and osmolality of the formulation vary by no more than ±10%. A decrease of no more than about 10%, preferably no more than about 5%, is typically observed. Aggregates typically form in no more than about 10%, preferably no more than about 5%.
[0106] The antibody drug conjugate "retains its physical stability" in the pharmaceutical formulation if it shows no significant increase in aggregation, precipitation, and / or denaturation as measured by visual inspection of color and / or clarity, or by UV light scattering, size exclusion chromatography (SEC), and dynamic light scattering (DLS). Changes in protein conformation can be assessed by fluorescence spectroscopy (which determines protein tertiary structure) and by FTIR spectroscopy (which determines protein secondary structure).
[0107] An antibody drug conjugate "retains its chemical stability" in a pharmaceutical formulation if it shows no significant chemical changes. Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein. Degradation processes that often change the chemical structure of a protein include hydrolysis or truncation (assessed by methods such as size exclusion chromatography and CE-SDS), oxidation (assessed by methods such as peptide mapping in combination with mass spectrometry or MALDI / TOF / MS), deamidation (assessed by methods such as ion exchange chromatography, capillary isoelectric focusing, peptide mapping, isoaspartate measurement), and isomerization (assessed by measuring isoaspartate content, peptide mapping, etc.).
[0108] An antibody drug conjugate "retains its biological activity" in a pharmaceutical formulation if the biological activity of the antibody drug conjugate at a given time is within a predetermined range of the biological activity exhibited when the pharmaceutical formulation is prepared.
[0109] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur. For example, "optionally comprising 1-3 antibody heavy chain variable regions" means that the antibody heavy chain variable region of the specified sequence may but need not be present.
[0110] The preparation of conventional pharmaceutical compositions can be found in the Chinese Pharmacopoeia.
[0111] The term "carrier" as used in the drugs disclosed herein refers to a system that can change the way a drug enters the human body and its distribution in the body, control the release rate of the drug, and deliver the drug to the targeted organ. Drug carrier release and targeting systems can reduce drug degradation and loss, reduce side effects, and improve bioavailability. For example, polymer surfactants that can be used as carriers can self-assemble to form various forms of aggregates due to their unique amphiphilic structure. Preferred examples include micelles, microemulsions, gels, liquid crystals, vesicles, etc. These aggregates have the ability to encapsulate drug molecules and have good permeability to membranes, making them excellent drug carriers.
[0112] "Administering" and "treating" as applied to an animal, a human, a laboratory subject, a cell, a tissue, an organ or a biological fluid, refers to the contacting of an exogenous drug, therapeutic agent, diagnostic agent or composition with an animal, a human, a subject, a cell, a tissue, an organ or a biological fluid. "Administering" and "treating" can refer to, for example, therapeutic, pharmacokinetics, diagnostics, research and experimental procedures. Treatment of cells includes contacting an agent with a cell, and contacting an agent with a fluid, wherein the fluid is in contact with the cell. "Administering" and "treating" also mean treating, for example, a cell in vitro and ex vivo, by an agent, a diagnostic, a binding composition or by another cell. "Treatment" as applied to a human, veterinary or research subject, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.
[0113] "Treatment" means administering an internal or external therapeutic agent, such as a composition comprising any of the antibody drug conjugates of the present disclosure, to a patient who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, a therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in a treated patient or population to induce regression of such symptoms or to inhibit the development of such symptoms to any clinically measurable extent. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") can vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether the symptoms of the disease have been alleviated can be evaluated by any clinical detection method commonly used by doctors or other health care professionals to evaluate the severity or progression of the symptoms. Although the embodiments of the present disclosure (e.g., methods of treatment or kits) may not be effective in alleviating every symptom of the target disease, they should alleviate the target disease symptoms in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t-test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.
[0114] An "effective amount" encompasses an amount sufficient to ameliorate or prevent the symptoms or conditions of a medical condition. An effective amount also means an amount sufficient to permit or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects.
[0115] "Displacement" refers to the replacement of the solvent system in which the antibody protein or antibody drug conjugate is dissolved. For example, the high-salt or hypertonic solvent system containing the antibody protein or antibody drug conjugate is replaced by a physical manipulation using the buffer system of the stabilizing formulation, thereby allowing the antibody protein or antibody drug conjugate to be present in the stabilizing formulation. Such physical manipulations include, but are not limited to, ultrafiltration, dialysis, or reconstitution followed by centrifugation.
[0116] Example
[0117] The present disclosure is further described below with reference to the following examples, but these examples are not intended to limit the scope of this disclosure. Experimental methods in the examples disclosed herein that do not specify specific conditions were generally performed according to conventional conditions, such as those in the Cold Spring Harbor Laboratory's "Antibody Techniques Laboratory Manual" and "Molecular Cloning Manual," or according to the conditions recommended by the raw material or product manufacturer. Reagents whose specific sources are not specified were commercially available.
[0118] 1. Antibody Preparation
[0119] Example 1. Construction of Nectin-4 High-Expression Cell Line
[0120] The PBABE-Nectin4 lentiviral expression vector plasmid and the pVSV-G and pGag-pol lentiviral system packaging vectors were transfected into 293T virus packaging cells using Lipofectamine 3000 transfection reagent. The virus-containing culture supernatant was collected, filtered, and subjected to ultrahigh-speed centrifugation. The concentrated virus was used to infect Chinese hamster ovary (CHO-K1) cells. After puromycin selection for two to three weeks, single-cell sorting was performed by FACS.
[0121] The expression of Nectin-4 on the surface of lentivirus-infected CHO-K1 cells was detected by FACS, and monoclonal cell lines with high Nectin-4 expression were selected, expanded and cultured, and frozen for future use.
[0122] Human nectin-4 amino acid sequence (UniProtKB-Q96NY8-1)
[0123] The positive control antibody EV201 was prepared according to (WO2012047724, page 115). The amino acid sequences of the heavy and light chains of EV201 (enfortumab vedotin) are as follows:
[0124] EV201 heavy chain:
[0125] EV201 light chain:
[0126] Example 2. Screening of anti-human nectin-4 monoclonal antibodies
[0127] The antibody disclosed herein is referenced from NEC49 in PCT / CN2022 / 089129. The entire text of PCT / CN2022 / 089129 is incorporated herein by reference. Using a fully human semi-synthetic phage antibody library and the antigen Biotinylated Human Nectin-4 (purchased from Beijing Biopsies Biotechnology Co., Ltd., catalog number: NE4-H82E7), after panning, phage detection was performed using the ELISA method to obtain positive clones. The positive clones were sequenced, and after obtaining the sequence, the positive clone sequence was inserted into the protein expression vector Phr-IgG and expressed on HEK293 and Expi-CHO-S. After purification, FACS and endocytic activity verification experiments were performed, and finally the fully human antibody molecule NEC49 was selected.
[0128] The variable region sequence of the fully human antibody molecule NEC49 is as follows:
[0129] NEC49 heavy chain variable region:
[0130] NEC49 light chain variable region:
[0131] Table 1. CDR sequences obtained by Kabat numbering rules
[0132] The above-mentioned anti-nectin4 antibody may further comprise an antibody heavy chain constant region and a light chain constant region; the heavy chain constant region may be selected from human IgG1, IgG2, IgG3, and IgG4 constant regions, and the light chain constant region may be selected from human antibody κ and λ chain constant regions. In the present disclosure, the antibody comprises a human IgG1 heavy chain constant region and a human κ light chain constant region. The sequence of the disclosed antibody molecule NEC49 is as follows:
[0133] NEC49 heavy chain:
[0134] NEC49 light chain:
[0135] 2. Construction of ADC molecules
[0136] ADC drug loading determination
[0137] The drug loading of ADC was determined by reverse phase high performance liquid chromatography (RP-HPLC).
[0138] 1. Determination method:
[0139] Naked antibody and test sample ADC (concentration 1 mg / mL) were reduced with 4 μL of DDT (Sigma), incubated in a 37°C water bath for 1 hour, and then removed to an inner tube. Detection was performed using an Agilent 1200 HPLC with an Agilent PLRP-S 1000A 8 μm 4.6 x 250 mm column, 80°C column temperature, DAD detector wavelength 280 nm, flow rate 1 mL / min, and injection volume 40 μL. The light and heavy chains were then identified by comparing the spectra of the sample with those of the naked antibody. The spectra of the test sample were then integrated to calculate the DAR value.
[0140] 2. Solution preparation
[0141] 1) 0.25M DTT solution:
[0142] 2) Mobile phase A (0.1% TFA aqueous solution):
[0143] 3) Mobile phase B (0.1% TFA acetonitrile solution):
[0144] 3. Data Analysis
[0145] By comparing the spectra of the sample and naked antibody, the positions of the light and heavy chains are distinguished, and then the spectrum of the test sample is integrated to calculate the drug loading DAR value. The calculation formula is as follows: LC peak area sum = LC peak area + LC +1 Peak area HC peak area sum = HC peak area + HC +1 Peak area + HC +2 Peak area + HC +3 Peak area LC DAR = Σ(number of connected drugs * peak area percentage) / LC peak area sum HC DAR = Σ(number of connected drugs * peak area percentage) / HC peak area sum DAR = LC DAR + HC DAR.
[0146] Example 3-1. ADC-1
[0147] To a solution of NEC49 antibody in PBS buffer (pH 6.5, 0.05 M PBS buffer; 10.0 mg / mL, 6.4 mL, 432 nmol) at 37°C, a prepared solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) (10 mM, 130 μL, 1300 nmol) was added. The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath.
[0148] Compound 9-A (prepared with 9-A in Example 9, 58-60, WO2020063676, 5.6 mg, 5214 nmol) was dissolved in 300 μL of DMSO and added to the above reaction solution. The mixture was placed in a water bath shaker and shaken at 25°C for 3 hours to stop the reaction. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: 0.05 M PBS buffer solution at pH 6.5, containing 0.001 M EDTA) to obtain an exemplary product ADC-1 of the title conjugate formula NEC49-9-A in PBS buffer (2.89 mg / mL, 21 mL), which was refrigerated and stored at 4°C. The average loading value calculated by RP-HPLC was n = 4.90.
[0149] Example 3-2. ADC-2
[0150] To a solution of control antibody EV201 in PBS buffer (pH 6.5, 0.05 M PBS buffer; 10.0 mg / mL, 1.63 mL, 110 nmol) at 37°C, add a solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) in water (10 mM, 28.5 μL, 285 nmol). Place the solution in a water bath shaker and incubate at 37°C for 3 hours to stop the reaction. Cool the reaction solution to 25°C in a water bath.
[0151] Compound 9-A (1.18 mg, 1100 nmol) was dissolved in 90 μL of DMSO and added to the above reaction solution. The mixture was placed in a water bath shaker and shaken at 25°C for 3 hours, after which the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: 0.05 M PBS buffered water at pH 6.5, containing 0.001 M EDTA) to obtain the exemplary product ADC-2 of the title conjugate formula EV201-9-A in PBS buffer (1.12 mg / mL, 12 mL). The product was stored refrigerated at 4°C. The average RP-HPLC calculated loading was n = 3.90.
[0152] Example 3-3. ADC-3
[0153] To a solution of antibody EV201 in PBS buffer (pH 6.5, 0.05 M PBS buffer; 10.0 mg / mL, 3.67 mL, 248 nmol) at 37°C was added a solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) in water (10 mM, 64.4 μL, 644 nmol). The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath.
[0154] Compound VcMMAE (Hanxiang Biotechnology, CAS 646502-53-6, 3.3 mg, 2480 nmol) was dissolved in 150 μL of DMSO and added to the above reaction solution. The mixture was shaken in a water bath at 25°C for 3 hours, and the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: 0.05 M PBS buffer, pH 6.5, containing 0.001 M EDTA) to obtain the exemplary product ADC-3 of the title conjugate formula EV201-MMAE in PBS buffer (2.71 mg / mL, 14 mL). The product was stored refrigerated at 4°C. The average RP-HPLC loading was calculated: n = 4.09.
[0155] Example 3-4. ADC-4
[0156] In 20 mM histidine-acetate-Tris buffer (pH 7.3) containing 2.5 mM EDTA, 186.37 g of the NEC49 antibody (1.28 mmol, diluted with 20 mM histidine-acetate to an antibody concentration of 23 mg / mL) and 0.8873 g of tris(2-carboxyethyl)phosphine hydrochloride (Sigma, 3.10 mmol) were stirred in a thermostatic water bath at 12°C for 100 minutes to produce a solution of Intermediate I. 2 M acetic acid was added dropwise to adjust the reaction solution to pH 5.0.
[0157] Compound 9-A (6.13 g, 5.71 mmol) was dissolved in 0.446 L of DMSO to generate a DMSO solution of compound 9-A. 0.365 L of DMSO was pre-added to the above-mentioned solution of Intermediate I. The DMSO solution of compound 9-A was then added to the pre-DMSO solution of Intermediate I. The reaction was stirred at 12°C for 100 minutes, and then stopped. This yielded the product ADC-4 (20 g / L, 175.93 g, average value calculated by reverse phase chromatography: n = 4.0).
[0158] Biological tests
[0159] Test Example 1. Antibody Protein Level Affinity and Kinetics Experiment
[0160] Anti-nectin-4 antibody affinity and binding kinetics were characterized using Biacore T200 (GE). IgG antibodies were affinity-captured using a Protein A biosensor chip (Cat.#29127556, GE). A concentration gradient of human nectin-4 His (Cat.#19771-H08H, Sino Biological) antigen diluted in HBS-EP buffer (pH 7.4) (Cat.#BR-1001-88, GE) was then passed over the chip surface. Antigen-antibody binding kinetics were tracked for 3 minutes and dissociation kinetics for 10 minutes. Binding and dissociation curves were obtained using a Biacore T200 instrument to monitor the reaction signals in real time. After each experimental cycle, the biosensor chip was washed and regenerated with 10 mM Gly-HCl, pH 1.5 (Cat.#BR-1003-54, GE). The data were analyzed using GE's BIAevaluation software with a 1:1 (Langmuir) binding model. The ka (kon), kd (koff), and KD values determined by this method are shown in Table 2-1.
[0161] Table 2-1. Antibody affinity determined by Biacore
[0162] Test Example 2. Antibody in vitro cell binding assay
[0163] Nectin4-CHOK1 / T47D / MDA-MB-468 cells were prepared into 1×10 6 / mL cell suspension, 100μL / well was added to a 96-well round-bottom plate. After centrifugation to remove the supernatant, 50μL / well of the test antibody diluted with FACS buffer at different concentrations was added, and the cells were incubated in a 4°C refrigerator in the dark for 1 hour. After washing three times with FACS buffer at 500g, Alexa Fluor 488 Goat anti-Human IgG (H+L) (invitrogen, A-11013) at a working concentration was added and the cells were incubated in a 4°C refrigerator in the dark for 40 minutes. After washing three times with FACS buffer at 500g, the geometric mean fluorescence intensity was detected on a BD FACSCantoII flow cytometer to calculate the EC value of the antibody binding to cells expressing Nectin-4. 50 The results are shown in Table 2-2.
[0164] Table 2-2. Antibody binding activity to different cells
[0165] in conclusion:
[0166] NEC49 has binding activity to multiple nectin-4 expressing cell lines and is superior to control molecules.
[0167] Test Example 3. DT3C Antibody Internalization Experiment
[0168] The purpose of this experiment is to indirectly reflect the internalization of Nectin-4 antibody based on the fact that after DT3C protein enters cells, activated DT kills cells. 50 The in vitro endocytic activity of the antibody was evaluated by measuring the cytotoxicity and maximum killing value.
[0169] DT3C is a recombinantly expressed fusion protein composed of Fragment A (toxin-only) of diphtheria toxin and Fragment 3C (IgG-binding portion) of group G Streptococcus. This protein has a high affinity for the Fc portion of antibodies and enters cells together with the antibody during endocytosis. Under the action of intracellular furin, DT is released, which is toxic. DT inhibits EF2-ADP ribosylation, blocks protein translation, and ultimately leads to cell death. DT3C that does not enter cells has no cytotoxic activity. The endocytic activity of antibodies is evaluated based on the cell killing effect.
[0170] Prepare Nectin4-CHOK1 cell suspension in fresh cell culture medium containing 20% low IgG FBS at a cell density of 2×10 4 Cells / mL were added to a 3903 cell culture plate at 50 μL / well and incubated at 37°C in 5% CO2 for 16 hours. DT3C was diluted to 1.6 μM and the antibody was diluted to 266.4 nM in serum-free medium. 80 μL of DT3C and 80 μL of antibody were mixed at a 1:1 ratio and incubated at room temperature for 30 minutes. The molar concentration of DT3C was 6 times that of the antibody.
[0171] The DT3C and antibody mixture was diluted four-fold in serum-free medium for a total of eight steps, with the ninth and tenth steps being pure medium. C25-IgG1 served as a negative control for the isotype IgG1. 50 μL of the diluted mixture was added to 50 μL of cells and incubated in an incubator for three days. 50 μL of CTG was added to each well and incubated at room temperature in the dark for 10 minutes. A white backing film was applied to the bottom of the cell culture plate, and chemiluminescence was read on a Victor 3 microplate reader. Results are shown in Table 3.
[0172] Table 3. In vitro endocytic activity of antibodies
[0173] Test Example 4. pHrodo Antibody Internalization Experiment
[0174] The purpose of this experiment is to reflect the internalization of the nectin-4 antibody based on the change in fluorescence signal after the dye is internalized. The intensity of the fluorescence signal is used to evaluate the antibody's in vitro endocytic activity.
[0175] Fab fragments conjugated to the pH-sensitive pHrodo iFL dye bind directly to the Fc region of the nectin-4 antibody without interfering with the antibody's antigen recognition. The pHrodo iFL dye is nearly nonfluorescent at neutral pH. During nectin-4 antibody endocytosis, the dye is internalized, and the fluorescence signal gradually increases as the pH decreases. The increase in fluorescence signal is used to evaluate the antibody's endocytic activity.
[0176] Nectin4-CHOK1 clone 3 cells were cultured in DMEM / F12 + 10% FBS + 10 μg / mL puromycin. On the first day of the experiment, a cell suspension was prepared in fresh cell culture medium at a density of 2×10 5 cells / mL, 100 μL / well was added to a 96-well cell culture plate and cultured at 37°C in 5% carbon dioxide for 24 hours.
[0177] 4× Antibody Preparation: Dilute the antibody stock solution 10-fold with FBS-free culture medium to prepare culture medium, and then dilute the culture medium to 4× Dosing Solution (80nM). The final antibody concentration is 20nM.
[0178] 4×Zenon TM pHrodo TM iFL IgG labeling reagent preparation: pHrodo TM Dilute the labeling reagent stock solution to 4× concentration (240nM) and the final concentration to 60nM. TM The labeling reagent solution was mixed in equal volumes and incubated at room temperature for 10 minutes. 50 μL of the mixture was added to 150 μL of serum-free culture medium to give each antibody sample two concentrations (20 nM and 5 nM).
[0179] Aspirate 50 μL of cell suspension from the 3903 plate and add 50 μL of the antibody and pHrodo dye mixture to each well. Set up two replicate wells for each antibody sample. Also set up a dye-only group and an isotype IgG1 control group.
[0180] After 24 hours of incubation in the incubator, the culture medium was aspirated, 50 μL of trypsin was added to each well, and digestion was continued for 2 minutes. Digestion was terminated with 50 μL of fresh culture medium. Cells from the same sample were transferred to the same well of a round-bottom plate using a dispenser. Centrifuge at 1500 rpm for 2 minutes, discard the culture medium, wash the cells once with FACS buffer (PBS + 2.5% FBS), and centrifuge at 1500 rpm for 2 minutes. Add 200 μL of FACS buffer (PBS + 2.5% FBS), resuspend the cells, and detect the FITC signal using a flow cytometer. Data were analyzed using Flowjo 7.6. The results of the endocytosis experiment of NEC49 and EV201 on Nectin4-CHOK1 clone3 (C25-IgG1 is the isotype IgG1 negative control group) are shown in Table 4.
[0181] Table 4. In vitro endocytic activity of antibodies
[0182] NEC49 has endocytic activity in Nectin4-CHOK1 cells using the pHrodo method and is superior to control molecules.
[0183] Test Example 5. ADC Molecular Cell Activity Experiment
[0184] The purpose of this experiment is to detect the cell killing effect of Nectin4-ADC samples. 50 The in vitro activity of Nectin4-ADC was evaluated by quantification of the cytotoxicity and maximal killing values.
[0185] T47D (human ductal mammary carcinoma cell line, HTB-133 TM ), MDA-MB-468 (human breast cancer cells, HTB-132 TM ) and MDA-MB-231 (human breast cancer cells, HTB-26 TM ) The cells were trypsinized, neutralized with fresh culture medium, centrifuged at 1000 rpm, and resuspended in culture medium. After counting, the cell suspension density was adjusted to 3703 cells / mL and 135 μL was added to each well of a 96-well cell culture plate 3903. Column 11 was not plated with cells, but only 135 μL of culture medium was added. The cells were cultured at 37°C with 5% CO2 for 16 hours.
[0186] ADC-1 and ADC-2 were diluted fivefold with PBS, starting with the stock solution concentration, for a total of eight concentrations. Remove the cell culture plate and add 15 μL of the 10× concentration solution to each well. Incubate at 37°C in a 5% CO2 atmosphere for 6 days.
[0187] 70 μL of CTG was added to each well and incubated at room temperature in the dark for 10 minutes. A white base film was attached to the bottom of the cell culture plate and placed on a Victor3 reader for chemiluminescence reading. Data from this experiment were processed using GraphPad Prism 5.0. The results are shown in Table 5.
[0188] Table 5. Cell killing by Nectin4-ADC drugs Note: + represents the expression level of Nectin4 on cells, and the more + marks, the higher the expression level.
[0189] NEC49-9-A (ADC-1) has a significant killing effect on cells with medium or high expression, and significantly reduced killing effect on cells with low or no expression, indicating that this molecule has higher selectivity and drug safety.
[0190] Test Example 6. In vivo efficacy evaluation of ADC molecule high expression CDX model
[0191] Estrogen tablets (0.36 mg / tablet) were subcutaneously inoculated into the left back of each Balb / c nude mouse. Three days later, 0.2 mL (10×10 6 T47D cells (with Matrigel, volume ratio of 1:1) were subcutaneously inoculated on the right back of each mouse, and the average tumor volume reached approximately 150 mm 3 The mice were divided into groups and 5 groups were used for drug administration, with 8 mice in each group.
[0192] The ADC compound (prepared with PBS) was injected intravenously for 3 times, with each mouse receiving an injection of 10 μL / g based on body weight. The blank solvent group was injected with PBS.
[0193] Tumor volume and body weight were measured twice weekly and the data were recorded. Data were recorded using Excel statistical software: mean values were calculated as avg; SD values were calculated as STDEV; and SEM values were calculated as STDEV / SQRT (number of animals in each group). Graphs were drawn using GraphPad Prism software, and statistical analyses were performed using two-way ANOVA or one-way ANOVA.
[0194] The formula for calculating tumor volume (V) is: V = 1 / 2 × L 长 ×L 短 2
[0195] Relative tumor growth rate (T / C%) = (T - T0) / (C - C0) × 100%, where T and C represent the tumor volumes of the treatment and control groups at the end of the experiment; T0 and C0 represent the tumor volumes at the beginning of the experiment. Tumor inhibition rate (TGI%) = 1 - T / C%.
[0196] The results are shown in Table 6.
[0197] Table 6. Efficacy of ADC on T47D xenografts in nude mice
[0198] In this study, the test compounds ADC-3 and ADC-1 significantly inhibited the growth of human breast cancer T47D cell xenografts in mice at all doses, with a clear dose-dependent effect. At the same dose, ADC-1 was more effective in inhibiting tumor growth than the control molecule.
[0199] Test Example 7. In vivo toxicity test of ADC molecules in rats
[0200] ADC compounds (prepared with physiological saline) were injected into the tail vein of SD rats (male, Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd.), with 4 rats per group, once a week for a total of 3 doses, with each rat receiving an injection of 5 mL / kg based on body weight. Experimental design:
[0201] Table 7. Dosage regimen for toxicity testing
[0202] The results showed that after the first dose, animals in Group A died, stopped eating, and experienced a sharp weight loss. The experiment was terminated and autopsies were performed, revealing adrenal enlargement and intussusception. After three consecutive doses, animals in Group B showed no clinical or post-mortem abnormalities. Coagulation function tests were normal in all groups. The results are shown in Table 8.
[0203] Table 8. Results of toxicity test of ADC compounds on SD rats Note: WBC (white blood cells), RET# (reticulocytes), LYM (lymphocytes), ALT (glycine aminotransferase), TBIL (total bilirubin)
[0204] in conclusion:
[0205] Animals in the ADC-3 group died after the first dose, and several blood and biochemical parameters were abnormal. After three consecutive doses, the ADC-1 group showed no abnormalities in clinical and autopsy observations. Coagulation function showed no abnormalities, and other parameters showed no significant abnormalities, except for a significant reduction in thymus size.
[0206] Preliminary rat toxicity test results suggest that ADC-1 has better in vivo safety and lower toxic side effects than the control molecule.
[0207] Test Example 8. ADC Molecular Pharmacokinetic Experiment
[0208] F344RG rats (male, Beijing Weitongda Biotechnology Co., Ltd.) were injected intravenously, with 4 rats in a group and a total of 1 dose, each of which was injected with 5 mL / kg and 10 mg / kg according to body weight. 0.2 mL of whole blood was collected before administration and 5 minutes, 8 hours, 1 day, 2 days, 4 days, 7 days, 10 days, 14 days, 21 days, and 28 days after administration. No anticoagulation was added. After blood collection, it was placed at 4°C for 30 minutes, centrifuged at 1000g for 15 minutes, and the supernatant (serum) was placed in an EP tube and stored at -80°C. Elisa was used to determine the antibody (total antibody) concentration and intact ADC concentration in the serum. The results are shown in Table 9. Experimental results:
[0209] Table 9. PK half-life and main pharmacokinetic parameters of F344 RG in rats
[0210] In rats, ADC-1 has good plasma stability.
[0211] 3. Preparation
[0212] The equipment used in the preparation and testing process and the calculation method of the results are as follows:
[0213] 1)SEC size exclusion chromatography:
[0214] An analytical method that separates solutes based on the relative relationship between the pore size of the gel and the coil size of the polymer sample molecules.
[0215] SEC% (SEC monomer content percentage) = A monomer / A total * 100% (A monomer is the peak area of the main peak monomer in the sample, and A total is the sum of all peak areas.)
[0216] △SEC% represents the difference between the detection item after placement under various conditions and the initial placement.
[0217] SEC instrument: Agilent 1260; columns: waters, XBrige SEC (300×7.8mm 3.5μm)
[0218] 2) R-CE capillary gel electrophoresis:
[0219] A method of electrophoresis in which gel is transferred to a capillary tube as a supporting medium and samples are separated according to their molecular weight at a certain voltage.
[0220] R-CE purity percentage = A main peak / A total * 100% (A main peak is the peak area of the light chain main peak + the heavy chain main peak in the sample, and A total is the sum of all peak areas.
[0221] R-CE measurement instrument: Beckman model plus800
[0222] △R-CE% indicates the difference between the detection item after placement under various conditions and the value at the beginning of placement.
[0223] 3) Turbidity measurement:
[0224] The degree of obstruction to light passing through the water layer indicates the water's ability to scatter and absorb light. This is related not only to the suspended solids content but also to the particle composition, size, shape, and surface reflectivity. By comparing the absorbance values of the same protein sample at the same concentration and wavelength (near-UV and visible wavelength regions), higher absorbance values indicate greater turbidity and a more pronounced tendency for protein molecules in the sample to aggregate. The measurement instrument is a multifunctional microplate reader (Molecular Devices M5). Equal volumes of sample are added to a 96-well plate and the absorbance values are read.
[0225] 4) Osmotic pressure measurement:
[0226] The freezing point method determines osmotic pressure based on the proportional relationship between freezing point depression and the molar concentration of a solution. It uses a highly sensitive temperature sensor to measure the freezing point of a solution and converts the electrical charge into osmotic pressure. Instrument manufacturer: Loser, model OM815.
[0227] 5) Protein concentration determination:
[0228] The concentration of the antibody drug conjugate in this disclosure is based on the concentration of the protein, that is, the concentration of the antibody portion in the antibody drug conjugate.
[0229] Because the toxin in the antibody drug conjugate absorbs at the protein characteristic absorption wavelength of 280nm, and the toxin also absorbs at 370nm, the following formula is used to calculate the above protein concentration: A 280nm =(C drug ×E drug-280 +C mAb ×E mAb-280 )×l A 370nm =C drug ×E drug-370 ×l
[0230] Pick
[0231] Right now:
[0232] Where,
[0233] A 280nm : The average absorbance of a single sample of the test solution at a wavelength of 280 nm when the optical path length is 1 cm;
[0234] A 370nm: The average absorbance of a single sample of the test solution at a wavelength of 370 nm when the optical path length is 1 cm;
[0235] E mAb-280 : The mass extinction coefficient of the protein at a wavelength of 280nm is 1.532g -1 cm -1 L;
[0236] E drug-280 : Mass extinction coefficient of toxin at 280nm wavelength, 5.17g -1 cm -1 L;
[0237] E drug-370 : Mass extinction coefficient of toxin at 370nm wavelength, 17.89g -1 cm -1 L;
[0238] R: the ratio of the toxin extinction coefficient at 370 nm to that at 280 nm, which is 3.46;
[0239] C mAb : protein concentration, mg / mL;
[0240] l: optical path length, cm (the optical path here is 1 cm).
[0241] If the test solution is diluted, the protein concentration is: C (mg / mL) = C mAb ×N, where N is the dilution multiple.
[0242] Protein concentration was determined using a UV-visible spectrophotometer (Nano Drop 2000).
[0243] Formulation Example 1. pH and buffer system screening
[0244] Formulations were prepared containing the buffer systems shown in Table 10, ADC-4 at a 20 mg / mL protein concentration, and polysorbate 80 (PS80) at 0.4 mg / mL. Forced degradation studies (40°C for one month) were conducted to investigate the effects of different buffer systems on protein stability, using SEC and R-CE as evaluation metrics.
[0245] The results are shown in Table 10. SEC and R-CE data showed that after one month at 40°C, the monomer purity of the preparation containing His-HCl (pH 6.0) was better than that of the other groups.
[0246] Table 10. pH and buffer system screening results Note: His-HCl stands for histidine-histidine hydrochloride; CA stands for citric acid-sodium citrate; SA stands for succinic acid-sodium succinate; PB stands for disodium hydrogen phosphate-sodium dihydrogen phosphate; 40℃ M1: Place at 40℃ for one month, the same below.
[0247] Formulation Example 2. Surfactant Screening
[0248] Formulations were prepared containing 10 mM His-HCl buffer, pH 6.0, ADC-4 at a protein concentration of 20 mg / mL, 80 mg / mL sucrose, and the surfactants shown in Table 11. Forced degradation studies (25°C, 300 rpm shaking for 10 days followed by 5 freeze-thaw cycles followed by 2 days at 25°C) were performed to investigate the effects of different surfactants on protein stability, using appearance, SEC, and R-CE as evaluation criteria.
[0249] The results are shown in Table 11. After forced degradation, the formulation containing 0.2 mg / mL PS80 was clear and transparent, with a better appearance than the other groups. SEC and R-CE data showed no significant difference in the purity of the formulations containing different surfactants.
[0250] Table 11. Surfactant screening results Note: PS80 stands for polysorbate 80; PS20 stands for polysorbate 20; PF68 stands for poloxamer 188; Shaking D10 stands for shaking for 10 days; F / T 5C+25℃D2 stands for 5 cycles of freeze-thaw from -25℃ to 2-8℃ + 25℃ for 2 days, the same below.
[0251] Formulation Example 3. Screening of ionic strength of buffer system
[0252] Formulations containing 10 mM to 30 mM His-HCl buffer at pH 6.0, ADC-4 at a protein concentration of 20 mg / mL, 0.2 mg / mL PS80, and 80 mg / mL sucrose were prepared, as shown in Table 12. Forced degradation studies (shaking at 300 rpm for 10 days) were performed on the samples to investigate the effects of different surfactant concentrations on protein stability, using post-displacement pH shift, appearance, SEC, and R-CE as evaluation criteria.
[0253] The results are shown in Table 12. After shaking for 10 days, the formulations with 10 mM and 30 mM ionic strengths were transparent and clear in appearance.
[0254] Table 12. Buffer system ionic strength screening table
[0255] Formulation Example 4. Screening of ionic strength of buffer system
[0256] Formulations containing 10 mM to 50 mM His-HCl buffer at pH 6.0, ADC-4 at a protein concentration of 20 mg / mL, 0.2 mg / mL PS80, and 80 mg / mL sucrose were prepared, as shown in Table 13. Forced degradation studies (40°C for one month) were conducted to investigate the effects of different surfactant concentrations on protein stability, using post-displacement pH shift, appearance, SEC, and R-CE as evaluation criteria.
[0257] The results are shown in Table 13. The formulations with different ionic strengths all appeared transparent and clear. SEC and R-CE data showed no significant difference in the purity of the formulations with different buffer ionic strengths.
[0258] Table 13. Buffer system ionic strength screening table
[0259] Formulation Example 5. Screening of excipients and osmotic pressure regulators
[0260] A formulation containing 30 mM pH 6.0 His-HCl buffer, 20 mg / mL protein concentration of ADC-4, and 0.2 mg / mL PS80 was prepared. The excipients (eg, sugar) and osmotic pressure regulator in the formulation are shown in Table 14 below.
[0261] Table 14. Excipients and osmotic pressure regulator information
[0262] Freeze-dried product: Inspect the appearance of the freeze-dried product. The freeze-drying procedure is shown in Table 15:
[0263] Table 15. Lyophilization procedure
[0264] The results are shown in Table 16. The appearance of the freeze-dried powder cake showed severe bottom collapse in the high sucrose concentration group. However, when the sucrose concentration was reduced to 40 mg / mL and glycine was added for freeze-drying, the resulting powder cake was uniform and plump, without collapse. This indicates that the primary drying time required after reducing the sucrose concentration and adding glycine is shorter than that required for the formulation with a higher sucrose concentration. The formulation containing 9 mg / mL glycine is preferred.
[0265] In the formulation with 9 mg / mL glycine added, there was no significant difference in the appearance of the freeze-dried powder between the sucrose group and the α,α-trehalose dihydrate group. Sucrose was selected as the excipient and was isotonic at a concentration of 40 mg / mL.
[0266] Table 16. Osmotic pressure regulator screening freeze-drying results
[0267] Formulation Example 6. Confirmation of Formulation
[0268] A stock solution containing ADC-4 at a 20 mg / mL protein concentration, 30 mM His-HCl, pH 6.0, 40 mg / mL sucrose, 0.2 mg / mL PS80, and 9 mg / mL glycine was prepared and lyophilized. Forced degradation stability was investigated using SEC and R-CE.
[0269] The results are shown in Table 17. After being stored at 40°C for one month, there were no significant changes in SEC and R-CE, indicating that the protein had good stability.
[0270] Table 17. Forced degradation stability results
Claims
1. A pharmaceutical composition comprising an antibody drug conjugate and a buffer, wherein the antibody drug conjugate has the structure shown in Formula NEC49-9-A: in: NEC49 is an anti-nectin-4 antibody comprising heavy chain HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10; and light chain LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13; preferably, the heavy chain variable region as shown in SEQ ID NO:4 and the light chain variable region as shown in SEQ ID NO:5; more preferably, the heavy chain as shown in SEQ ID NO:6 and the light chain as shown in SEQ ID NO:7; n is a decimal or integer from 1 to 10, preferably from 1 to 8, more preferably from 3 to 5; The buffer is histidine-histidine hydrochloride buffer, The pH of the pharmaceutical composition is about 5.0 to about 6.5, preferably about 5.5 to about 6.5, and more preferably about 5.9 to about 6.
2.
2. The pharmaceutical composition according to claim 1, wherein the concentration of the buffer is about 10 mM to about 50 mM, preferably about 20 mM to about 40 mM, more preferably about 30 mM.
3. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutical composition further comprises a surfactant, wherein the surfactant is preferably polysorbate, more preferably polysorbate 80 or polysorbate 20, and most preferably polysorbate 80.
4. The pharmaceutical composition according to claim 3, wherein the surfactant concentration is about 0.05 mg / mL to about 0.4 mg / mL, preferably about 0.1 mg / mL to about 0.3 mg / mL, and more preferably about 0.2 mg / mL. 5 . The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition further comprises sugar, preferably selected from sucrose and α,α-trehalose dihydrate, more preferably sucrose.
6. The pharmaceutical composition according to claim 5, wherein the sugar concentration is about 25 mg / mL to about 80 mg / mL, preferably about 30 mg / mL to about 50 mg / mL, and more preferably about 40 mg / mL.
7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the pharmaceutical composition further comprises an amino acid, preferably glycine.
8. The pharmaceutical composition according to claim 7, wherein the concentration of the amino acid is about 6 mg / mL to about 15 mg / mL, preferably about 7 mg / mL to about 11 mg / mL, and more preferably about 9 mg / mL.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the antibody drug conjugate concentration is about 1 mg / mL to about 100 mg / mL based on protein concentration, Preferably, the concentration of the antibody drug conjugate is about 10 mg / mL to about 30 mg / mL based on protein concentration. More preferably, the concentration of the antibody drug conjugate is about 18 mg / mL to about 22 mg / mL based on protein concentration.
10. The pharmaceutical composition according to any one of claims 1 to 9, comprising: (a) the antibody drug conjugate at a protein concentration of about 10 mg / mL to about 30 mg / mL, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate, (c) about 30 mg / mL to about 50 mg / mL of sucrose or α,α-trehalose dihydrate, (d) about 7 mg / mL to about 11 mg / mL glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; The pH of the pharmaceutical composition is about 5.5 to 6.5; Preferably, the pharmaceutical composition comprises: (a) the antibody drug conjugate at a protein concentration of about 10 mg / mL to about 30 mg / mL, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate 80, (c) about 30 mg / mL to about 50 mg / mL of sucrose, (d) about 7 mg / mL to about 11 mg / mL glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; The pH of the pharmaceutical composition is about 5.5 to 6.5; More preferably, the pharmaceutical composition comprises: (a) the antibody drug conjugate at a protein concentration of about 10 mg / mL to about 30 mg / mL, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate 80, (c) about 30 mg / mL to about 50 mg / mL of sucrose, (d) about 7 mg / mL to 11 mg / mL glycine, and (e) about 20 mM to about 40 mM histidine-histidine hydrochloride buffer; The pH of the pharmaceutical composition is about 5.5 to 6.5; Most preferably, the pharmaceutical composition comprises: (a) the antibody drug conjugate at a protein concentration of about 18 mg / mL to about 22 mg / mL, (b) about 0.2 mg / mL of polysorbate 80, (c) about 40 mg / mL of sucrose, (d) about 9 mg / mL glycine, and (e) about 30 mM histidine-histidine hydrochloride buffer, The pH of the pharmaceutical composition is about 5.9 to 6.
2.
11. A lyophilized preparation containing an antibody drug conjugate, characterized in that The lyophilized preparation can be reconstituted to form the pharmaceutical composition according to any one of claims 1 to 10. 12 . A lyophilized preparation containing an antibody drug conjugate, the lyophilized preparation being obtained by freeze-drying the pharmaceutical composition according to claim 1 .
13. A reconstitution solution containing an antibody drug conjugate, characterized in that The reconstitution solution is prepared by reconstituted the lyophilized preparation containing the antibody drug conjugate according to claim 11 or 12; Preferably, the reconstitution solution comprises the following components: (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate, (c) about 30 mg / mL to about 50 mg / mL of sucrose or α,α-trehalose dihydrate, (d) about 7 mg / mL to about 11 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5 to 6.5; More preferably, the pharmaceutical composition comprises: (a) about 10 mg / mL to about 30 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.1 mg / mL to about 0.3 mg / mL of polysorbate 80, (c) about 30 mg / mL to about 50 mg / mL of sucrose, (d) about 7 mg / mL to about 11 mg / mL of glycine, and (e) about 10 mM to about 50 mM histidine-histidine hydrochloride buffer; the pH of the pharmaceutical composition is about 5.5 to 6.5; Most preferably, the pharmaceutical composition comprises: (a) about 18 mg / mL to about 22 mg / mL of the antibody drug conjugate, based on protein concentration, (b) about 0.2 mg / mL of polysorbate 80, (c) about 40 mg / mL of sucrose, (d) about 9 mg / mL of glycine, and (e) about 30 mM histidine-histidine hydrochloride buffer, wherein the pharmaceutical composition has a pH of about 5.9 to 6.
2. 14 . A drug kit comprising a container containing the pharmaceutical composition according to claim 1 , the lyophilized formulation containing an antibody-drug conjugate according to claim 11 or 12 , or the reconstituted solution containing an antibody-drug conjugate according to claim 13 .
15. Use of the pharmaceutical composition according to any one of claims 1 to 10, the lyophilized formulation containing an antibody-drug conjugate according to claim 11 or 12, or the reconstituted solution containing an antibody-drug conjugate according to claim 13 in the preparation of a medicament for treating a disease or condition mediated by nectin-4.
16. Use of the pharmaceutical composition according to any one of claims 1 to 10, the lyophilized formulation containing an antibody-drug conjugate according to claim 11 or 12, or the reconstituted solution containing an antibody-drug conjugate according to claim 13 in the preparation of a medicament for treating viral infection, tumor or cancer; preferably, the tumor or cancer is selected from urothelial carcinoma, ureteral cancer, breast cancer, pancreatic cancer, lung cancer, kidney cancer, liver cancer, esophageal cancer, laryngeal cancer, pharyngeal cancer, oral cancer, gastric cancer, ovarian cancer, prostate cancer, bladder cancer, colorectal cancer, head and neck cancer, squamous cell carcinoma and melanoma.
Citation Information
Patent Citations
Antibodies having specificity to nectin-4 and uses thereof
CN110392697A
Anti-Nectin-4 antibody and application thereof
CN113527486A
Nectin-4 for target genes of cancer therapy and diagnosis
US20110301056A1
Anti-nectin-4 antibody and Anti-nectin-4 antibody-drug conjugate, and medicinal user thereof
WO2022228406A1
Cited By
Antibody coupling medicine and application thereof
CN120267848A
Antibody-drug conjugate and use thereof
EP4840470A1
Antibody-drug conjugate and use thereof
WO2025148868A1
